RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype

Cancer Research

Volumn 70, Issue 20, 2010, Pages 7905-7917

  Yang, Dazhi ^a   Kedei, Noemi ^a   Li, Luowei ^a   Tao, Juan ^a   Velasquez, Julia F ^a   Michalowski, Aleksandra M ^a   Tóth, Balázs I ^b   Marincsák, Rita ^b   Varga, Attila ^b   Bíró, Tamás ^b   Yuspa, Stuart H ^a   Blumberg, Peter M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE B; RAS GUANINE NUCLEOTIDE RELEASING PROTEIN 3; RAS PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; XENOGRAFT;

CELL DIVISION; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MALE; PHENOTYPE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 78049277177     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4729     Document Type: Article

References (50)

1. Erlich S, Tal-Or P, Liebling R, et al. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol 2006;72:427-36. (Pubitemid 44061749)
2. McPherson RA, Conaway MC, Gregory CW, Yue W, Santen RJ. The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro. Prostate 2004;58:325-34. (Pubitemid 38295026)
3. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003;63:1981-9. (Pubitemid 36460867)
4. Bakin RE, Gioeli D, Bissonette EA, Weber MJ. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003;63:1975-80. (Pubitemid 36460866)
5. Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science 2001;294:1299-304. (Pubitemid 33063089)
6. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993;366:643-54. (Pubitemid 24036012)
7. Ehrhardt A, Ehrhardt GR, Guo X, Schrader JW. Ras and relatives-job sharing and networking keep an old family together. Exp Hematol 2002;30:1089-106.
8. Stone JC. Regulation of Ras in lymphocytes: get a GRP. Biochem Soc Trans 2006;34:858-61.
9. Suzuki T, Shen H, Akagi K, et al. New genes involved in cancer identified by retroviral tagging. Nat Genet 2002;32:166-74. (Pubitemid 34977213)
10. Ebinu JO, Bottorff DA, Chan EY, Stang SL, Dunn RJ, Stone JC. RasGRP, a Ras guanyl nucleotide-releasing protein with calcium-and diacylglycerol-binding motifs. Science 1998;280:1082-6.
11. Tognon CE, Kirk HE, Passmore LA, Whitehead IP, Der CJ, Kay RJ. Regulation of RasGRP via a phorbol ester-responsive C1 domain. Mol Cell Biol 1998;18:6995-7008.
12. Zheng Y, Liu H, Coughlin J, Zheng J, Li L, Stone JC. Phosphorylation of RasGRP3 on threonine 133 provides a mechanistic link between PKC and RAS signaling systems in B cells. Blood 2005;105:3648-54. (Pubitemid 40628212)
13. Lorenzo PS, Kung JW, Bottorff DA, Garfield SH, Stone JC, Blumberg PM. Phorbol esters modulate the Ras exchange factor RasGRP3. Cancer Res 2001;61:943-9.
14. Aiba Y, Oh-hora M, Kiyonaka S, et al. Activation of RasGRP3 by phosphorylation of Thr-133 is required for B cell receptor-mediated Ras activation. Proc Natl Acad Sci U S A 2004;101:16612-7. (Pubitemid 39557761)
15. Brodie C, Steinhart R, Kazimirsky G, et al. PKCδ associates with and is involved in the phosphorylation of RasGRP3 in response to phorbol esters. Mol Pharmacol 2004;66:76-84. (Pubitemid 38822089)
16. Kawasaki H, Springett GM, Toki S, et al. A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. Proc Natl Acad Sci U S A 1998;95:13278-83. (Pubitemid 28509562)
17. Yamashita S, Mochizuki N, Ohba Y, et al. CalDAG-GEFIII activation of Ras, R-ras, and Rap1. J Biol Chem 2000;275:25488-93.
18. Teixeira C, Stang SL, Zheng Y, Beswick NS, Stone JC. Integration of DAG signaling systems mediated by PKC-dependent phosphorylation of RasGRP3. Blood 2003;102:1414-20. (Pubitemid 36988051)
19. Roberts DM, Anderson AL, Hidaka M, et al. A vascular gene trap screen defines RasGRP3 as an angiogenesis-regulated gene required for the endothelial response to phorbol esters. Mol Cell Biol 2004;24:10515-28. (Pubitemid 39603114)
20. Coughlin JJ, Stang SL, Dower NA, Stone JC. RasGRP1 and RasGRP3 regulate B cell proliferation by facilitating B cell receptor-Ras signaling. J Immunol 2005;175:7179-84.
21. Yu YP, Landsittel D, Jing L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22:2790-9. (Pubitemid 41079896)
22. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51. (Pubitemid 46026500)
23. Wu B. Cancer outlier differential gene expression detection. Biostatistics 2007;8:566-75.
24. Mickey DD, Stone KR, Wunderli H, Mickey GH, Vollmer RT, Paulson DF. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res 1977;37:4049-58.
25. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
26. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
27. Troyer DA, Tang Y, Bedolla R, et al. Characterization of PacMetUT1, a recently isolated human prostate cancer cell line. Prostate 2008;68:883-92. (Pubitemid 351845219)
28. Hurle RA, Davies G, Parr C, et al. Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol Histopathol 2005;20:1339-49. (Pubitemid 41489177)
29. Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 2004;91:31-67. (Pubitemid 39140956)
30. Kamikura DM, Khoury H, Maroun C, Naujokas MA, Park M. Enhanced transformation by a plasma membrane-associated met oncoprotein: activation of a phosphoinositide 3′-kinase-dependent autocrine loop involving hyaluronic acid and CD44. Mol Cell Biol 2000;20:3482-96. (Pubitemid 30243894)
31. Ikediobi ON, Davies H, Bignell G, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5:2606-12.
32. Pu Y, Perry NA, Yang D, et al. A novel diacylglycerol-lactone shows marked selectivity in vitro among C1 domains of protein kinase C (PKC) isoforms α and δ as well as selectivity for RasGRP compared with PKCα. J Biol Chem 2005;280:27329-38.
33. Blagosklonny MV, Dixon SC, Robey R, Figg WD. Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines. Int J Oncol 2001;18:697-704.
34. Powell CT, Brittis NJ, Stec D, Hug H, Heston WD, Fair WR. Persistent membrane translocation of protein kinase C α during 12-0-tetrade- canoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ 1996;7:419-28.
35. Carter BS, Epstein JI, Isaacs WB. Ras gene mutations in human prostate cancer. Cancer Res 1990;50:6830-2.
36. Gumerlock PH, Poonamallee UR, Meyers FJ, deVere White RW. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 1991;51:1632-7.
37. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91:13-25.
38. Oki-Idouchi CE, Lorenzo PS. Transgenic overexpression of RasGRP1 in mouse epidermis results in spontaneous tumors of the skin. Cancer Res 2007;67:276-80.
39. Lauchle JO, Kim D, Le DT, et al. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature 2009;461:411-4.
40. Nagakawa O, Yamagishi T, Fujiuchi Y, et al. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer. Eur Urol 2005;48:686-90.
41. Nishimura K, Kitamura M, Miura H, et al. Prostate stromal cell-derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumor-stromal interaction. Prostate 1999;41:145-53.
42. Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386-96.
43. Kurimoto S, Moriyama N, Horie S, et al. Co-expression of hepatocyte growth factor and its receptor in human prostate cancer. Histochem J 1998;30:27-32.
44. Nishimura K, Kitamura M, Takada S, et al. Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor. Int J Urol 1998;5:276-81.
45. Yasuda K, Nagakawa O, Akashi T, et al. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Prostate 2009;69:346-51.
46. Davies G, Martin TA, Ye L, Lewis-Russell JM, Mason MD, Jiang WG. Phospholipase-Cγ-1 (PLCγ-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells. Urol Oncol 2008;26:386-91. (Pubitemid 351885372)
47. Bell WC, Myers RB, Hosein TO, Oelschlager DK, Grizzle WE. The response of extracellular signal-regulated kinase (ERK) to androgeninduced proliferation in the androgen-sensitive prostate cancer cell line, LNCaP. Biotech Histochem 2003;78:11-6.
48. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 1999;68:965-1014. (Pubitemid 29449213)
49. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310.
50. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 2006;38:200-11. (Pubitemid 43675585)